Catalyst Wire Dossier Catalyst Wire Dossier

Budesonide orodispersible tablet (once-daily vs twice-daily dosing)

budesonide · Dr. Falk Pharma GmbH
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for Budesonide orodispersible tablet (once-daily vs twice-daily dosing), covering 2026-03-11 to 2026-03-11. Get the full timeline:

Most recent: Clinical Trial Update: Once Daily Versus Twice Daily Budesonide Orodispersible Tablets for Induction of Remission in EoE [Phase 3]

See pricing